t form of skin cancer.
The US Food and Drug Administration approved relatlimab from a class known as LAG-3 inhibitors - short for lymphocyte-activation gene 3 - for use in combination with Bristol's blockbuster immunotherapy Opdivo as an initial treatment for advanced melanoma. The medicine is Bristol Myers' third approved cancer immunotherapy - drugs that enlist the body's defences in the fight against tumours. Opdivo targets a protein called PD-1.Relatlimab will only be used in combination with Opdivo, Chief Medical Officer Samit Hirawat said in an interview.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: